Key Points
- Insider sale: Christopher Joyce sold 19,706 shares on Dec. 8 at an average price of $19.33 for about $380,917, trimming his stake by 5.74% to 323,886 shares (≈$6.26M), according to an SEC filing.
- Mixed fundamentals: Alignment Healthcare reported $0.02 EPS (vs. -$0.01 est.) and revenue of $993.7M (+43.5% YoY) on Oct. 30, yet remains unprofitable with a -0.57% net margin and negative ROE; market cap is about $3.87B and P/E is -161.
- Market view and ownership: Analysts carry a consensus "Moderate Buy" with a $20.05 price target, and institutional investors dominate ownership (≈86.19%), led by Vanguard's 11.1M-share position.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) insider Christopher Joyce sold 19,706 shares of the business's stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $19.33, for a total transaction of $380,916.98. Following the transaction, the insider directly owned 323,886 shares in the company, valued at approximately $6,260,716.38. The trade was a 5.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Alignment Healthcare Price Performance
Alignment Healthcare stock opened at $19.36 on Tuesday. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 1.99. The company has a 50-day moving average price of $17.45 and a 200 day moving average price of $15.71. Alignment Healthcare, Inc. has a 12-month low of $10.18 and a 12-month high of $21.06. The stock has a market cap of $3.87 billion, a P/E ratio of -161.33 and a beta of 1.16.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.03. The company had revenue of $993.70 million for the quarter, compared to analyst estimates of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. Alignment Healthcare's revenue was up 43.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.14) EPS. Sell-side analysts anticipate that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.
Hedge Funds Weigh In On Alignment Healthcare
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Alignment Healthcare by 13.2% in the 1st quarter. Vanguard Group Inc. now owns 11,113,896 shares of the company's stock valued at $206,941,000 after acquiring an additional 1,295,825 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Alignment Healthcare in the first quarter valued at approximately $4,293,000. Invesco Ltd. grew its holdings in shares of Alignment Healthcare by 1,415.7% in the first quarter. Invesco Ltd. now owns 1,875,790 shares of the company's stock valued at $34,927,000 after purchasing an additional 1,752,033 shares in the last quarter. Entropy Technologies LP purchased a new stake in Alignment Healthcare during the 1st quarter worth approximately $627,000. Finally, Aigen Investment Management LP lifted its holdings in Alignment Healthcare by 392.7% during the 1st quarter. Aigen Investment Management LP now owns 56,545 shares of the company's stock worth $1,053,000 after buying an additional 45,069 shares in the last quarter. 86.19% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
ALHC has been the subject of several analyst reports. UBS Group increased their price objective on Alignment Healthcare from $17.00 to $18.00 and gave the stock a "neutral" rating in a research report on Friday, October 31st. KeyCorp reiterated an "overweight" rating on shares of Alignment Healthcare in a report on Monday, November 24th. The Goldman Sachs Group restated a "buy" rating and issued a $22.00 price objective on shares of Alignment Healthcare in a report on Monday, November 3rd. Zacks Research lowered shares of Alignment Healthcare from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 28th. Finally, JPMorgan Chase & Co. upgraded shares of Alignment Healthcare from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $18.00 to $20.00 in a research report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $20.05.
Check Out Our Latest Stock Analysis on Alignment Healthcare
About Alignment Healthcare
(
Get Free Report)
Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
